![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Advisory Committees Turn Down Opana IR Pediatric Labeling
Advisory Committees Turn Down Opana IR Pediatric Labeling
October 7, 2019
Two FDA advisory committees voted 16-8 against recommending pediatric labeling for Endo Pharma’s Opana IR (immediate-release oxymorphone).
Some members feared that adding pediatric information to the label would falsely imply that the agency approved a pediatric indication for the drug.
The committees also voted 20-5 in favor of the FDA continuing its current post-market safety monitoring requirement for OxyContin (oxycodone hydrochloride) extended-release tablets in pediatric patients.
Despite their support, members expressed concern about the abuse potential for opioid analgesics in pediatric patients.
Upcoming Events
-
21Oct